Figure 2 shows the differences in TNM and American Joint Committee on Cancer Code staging between EGFR mutant NSCLC and tumors with other mutations. EGFR mutant cancers were more likely to involve lymph nodes and to metastasize. EGFR mutant tumors were about as likely to be diagnosed as stage II, III, and IV as compared to tumors with other mutations. Here, EGFR is linked to cancer.